30-05-2025
Goldman Sachs Sticks to Their Hold Rating for Tandem Diabetes Care (TNDM)
In a report released yesterday, from Goldman Sachs maintained a Hold rating on Tandem Diabetes Care (TNDM – Research Report). The company's shares closed yesterday at $21.28.
Confident Investing Starts Here:
In addition to Goldman Sachs, Tandem Diabetes Care also received a Hold from Wells Fargo's Larry Biegelsen in a report issued on May 28. However, on May 20, Lake Street maintained a Buy rating on Tandem Diabetes Care (NASDAQ: TNDM).
TNDM market cap is currently $1.43B and has a P/E ratio of -7.60.
Based on the recent corporate insider activity of 56 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of TNDM in relation to earlier this year. Most recently, in March 2025, Jean-Claude Kyrillos, the EVP & COO of TNDM bought 10,538.00 shares for a total of $190,948.56.
